Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
Authors
Rampotas, A.Carter-Brzezinski, Luke
Somervaille, Tim C P
Forryan, J.
Panitsas, F.
Harrison, C.
Witherall, R.
Innes, A. J.
Wallis, L.
Butt, N. M.
Psaila, B.
Mead, A. J.
Carter, M.
Godfrey, A. L.
Laing, H.
Garg, M.
Francis, S.
Ewing, J.
Teh, C. H.
Cowen, H. B.
Dyer, P.
McConville, C.
Wadelin, F.
Sahra, A.
McGregor, A.
Kulakov, E.
McLornan, D. P.
Lambert, J.
Affiliation
Cancer Research UK Manchester Institute, Manchester, United Kingdom. Haematology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2024
Metadata
Show full item recordAbstract
Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.Citation
Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, et al. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024 Jan 11;143(2):178-82. PubMed PMID: 37963262.Journal
BloodDOI
10.1182/blood.2023022345PubMed ID
37963262Additional Links
https://dx.doi.org/10.1182/blood.2023022345Type
CorrespondenceLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood.2023022345
Scopus Count
Collections
Related articles
- A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
- Authors: Lin JQ, Li SQ, Li S, Kiamanesh EF, Aasi SZ, Kwong BY, Su Chang AL
- Issue date: 2022 Feb
- Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
- Authors: Yacoub A, Odenike O, Verstovsek S
- Issue date: 2014 Dec
- The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
- Authors: Greenfield G, McPherson S, Mills K, McMullin MF
- Issue date: 2018 Dec 17
- Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera.
- Authors: Gambichler T, Stockfleth E, Susok L
- Issue date: 2022 Jan
- Patient with eosinophilic dermatosis of myeloproliferative disease presenting with generalized erythematous plaques - Response to Ruxolitinib.
- Authors: Sun Y, Hsiao HH, Lan CE
- Issue date: 2021 Nov